Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. (not Talpher, Inc.) on March 10, 2022. The filing serves to announce the company's financial results for the three and twelve months ended December 31, 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not disclose specific material changes versus prior periods. It only indicates that the results for the periods ended December 31, 2021, have been announced.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934. It explicitly states that this information shall not be incorporated by reference into other filings unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Verify the correct registrant name is AcelRx Pharmaceuticals, Inc. (ACRX), not Talpher, Inc.
- Review Exhibit 99.1 (Press Release dated March 10, 2022) for actual financial figures, as they are absent from this summary text.
- Confirm the reporting period covers the three and twelve months ended December 31, 2021.
- Note that the financial data is "furnished" and not subject to the liabilities of Section 18 of the Exchange Act.